



**EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

**MINUTES OF THE MEETING HELD ON WEDNESDAY 19TH SEPTEMBER
2018 AT 12.30pm**

**IN SEMINAR ROOM 2, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL**

PRESENT:

Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting Chair)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Dr T MacKenzie (TM)	GP, EL CCG
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Dr K Burch (KB)	Consultant Microbiologist ELHT

In Attendance

Ms L Prince	Medicines Management Technician EL CCG
-------------	--

2018/126: APOLOGIES:

Dr D Gavan (DG)	Consultant Radiologist ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mrs C Harding (CH)	Pharmacist LCFT (representing Ms S Ramdour)

2018/127: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2018/128: MINUTES OF JULY MEETING:

Accepted as a correct record.

2018/129: MATTERS ARISING:

2018/052: LMMG Recommendations (from Feb LMMG) - Melatonin guidelines –

Updated guideline incorporating LCFT elements into local guideline now received.

Comments received:

- Make reference on page 5 to the capsules being unlicensed.
- Page 7 to clarify point 3 in the transition to adult services section.

VG to follow up with specialist.

2018/132 Melatonin – Prescribing Information Sheet (LMMG Recommendation)

This LMMG melatonin information sheet is not relevant to ELHE which does not use circadin so not adopted by the ELHE.

2018/073: Rifaxamin – Guidelines for Prescribing – Document sent but no comments received – AG to follow up.

2018/116: LMMG Recommendations (from June LMMG) – Paravit-CF® – is more cost effective than individual constituents. Add to formulary for use in cystic fibrosis patients.
Traffic Light: Amber

2018/130: LMMG CONSULTATIONS (for Sept LMMG) – comments sent but consultations reopened for further comments.

Headache Management Guideline – no comments

Zoladex 3.6mg Shared Care Guideline – reference to Appendix D but it is not included.

Zoladex 10.8mg Shared Care Guideline – reference to Appendix D but it is not included. Comments from SJ on measuring blood glucose, blood pressure & interval of monitoring sent in by CCG.

Actipatch Recommendation – concerns that trials were placebo controlled, small numbers, short term with lack of long term follow up. CCGs consider Black traffic light would be appropriate. LR to submit their comments to LMMG.

Rituximab in Idiopathic Thrombocytopenia Purpura (ITP) Recommendation – agree

Rituximab in Autoimmune Haemolytic Anaemia (AIHA) Recommendation – agree

Psoriasis Pathway updated – no additional comments

Prescribing for Clinical Need Policy – fungal nail infections may need treating and some dry eye problems need ophthalmology advice and treatment.

Resolved: Comments sent/to be sent to LMMG

2018/131: LMMG CONSULTATIONS (for Oct LMMG)

Combined adult & child ADHD Shared Care Guideline – Comments as follows:

- Appendix A refers to monitoring & review carried out by LCFT – any reference to LCFT needs to be changed to ‘secondary care provider’ or similar as LCFT is only one of the providers.
- Appendix A refers to ‘systolic blood pressure greater than 95th percentile’ – clarity required on definition and question raised over availability of small cuff size.
- Appendix A states ECG only at baseline if clinical diagnosis. This differs from updated NICE guidance that suggests baseline ECG when starting medication that could prolong QT interval (which would include Atomoxetine/Guanfacine)
- Page 4 Methylphenidate – ‘Prescribe by brand’ should be emphasised in bold.
- Page 5 Methylphenidate – Xaggitin XL to be added to the brands for MR tablets 18/27/36/54mg – this is current brand held on hospital contract.
- Reference is made to Appendix D (Shared care agreement form) but this is not included.

Testosterone Shared Care Guideline – Comments as follows:

- Page 2 Adverse effects – remove reference to women as this document is targeted at use in males.
- Appendix A – Monitoring PSA states twice yearly in the elderly, but a question was raised whether it should be done at all in the over 75’s
- Reference is made to Appendix D which is not included.
- A concern was raised with respect to the clinical evidence for testosterone in this indication, and whether a full evidence review should be undertaken.

Lixisenatide – Traffic Light Change – Comments as follows:

Review the guideline with the other GLP-1s in the pathway. Question was raised as to whether a third GLP1 is required and suggestion that the most cost effective should be used first line. There is also a wider issue with prescribing of GLP-1s in general both with and without insulin without attaining desired outcomes as defined by NICE.

Opicapone – Traffic Light Change – supported.

Resolved: Comments to be sent to LMMG

2018/132: LMMG RECOMMENDATIONS (from July LMMG)

Evolocumab for prevention of cardiac events in patients with CHD and a history of ACS with a statin Recommendation – accepted as written for use in ELHE.

Traffic Light: Black

Imiquimod 5% cream & Fluorouracil 5% cream Recommendation - accepted as written for use in ELHE.

Traffic light: Red

Transient Ischaemic Attack (TIA) Pathway – Appendix 1 in the Pathway for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation. Accepted as written for use in ELHE.

Melatonin – Prescribing Information Sheet – see above under item 2018/129

Phenylketonurea (PKU) Position Statement - accepted as written for use in ELHE.

2018/133: FORMULARY UPDATES

Pigmanorm® – although branded this is still unlicensed. **Traffic light to remain Red.**

Testosterone gel, Testogel® pump presentation – to replace sachets, care with dose required that is in pump actuations. Contains 60 actuations per pump.

Traffic Light: Amber

Glycopyrronium bromide oral solution – minutes from June 2017 - Remove ‘that is licensed in children aged 3 years and over’.

Mesalazine suppositories – Asacol® brand discontinued – replace with Salofalk®.

Methylphenidate – local shared care updated to include Xaggitin XL as a brand for the 18/27/36/54mg MR tablets.

Chlordiazepoxide – change from green to Amber traffic light as it should be started by specialist services.

Traffic Light: Amber

Extra items

Tadalafil once daily – remove from formulary in line with LMMG and national guidance.

Traffic light: Black

Adrenaline auto injector pens – national supply issues with 150microgram and 300microgram pens. Advice sought from paediatrics.

LR to produce & circulate a HOT Topic, with input from paediatrics.

Resolved: Formulary to be updated as above

2018/134: ANTIMICROBIAL GUIDELINES – SPLENECTOMY PROPHYLAXIS UPDATE

Splenectomy prophylaxis updated with new dose for phenoxymethylpenicillin.

Resolved: Updated Antimicrobial Guidelines acknowledged.

2018/135: VITAMIN D SUPPLIES FOR PAEDIATRICS

Paediatricians concerned that many GPs are refusing to prescribe Vitamin D for treatment when requested. Letters to recommend treatment are sent as the assay results and bloods are reported after clinic appointments. CCGs will advise GPs to prescribe when requested from paediatrics. Consultants to be reminded that Vitamin D maintenance should be managed through self-care. To be included in a Hot Topic for GPs.

Resolved: GPs to prescribe treatment dose Vitamin D for paediatrics on request with ongoing maintenance to be purchased under self-care. Include in HOT Topic.

2018/136: ELHT: GUIDANCE FOR MANAGEMENT OF BLEEDING IN PATIENTS TAKING DOAC'S - UPDATED

Guidance updated with reference to Andexant reversal agent removed as still not available in UK.

Resolved: The updated Guidance for Management of Bleeding in patients taking DOACs acknowledged.

2018/137: ELHT: SYRINGE PUMP POLICY - RANITIDINE

Monograph for Ranitidine to add to the syringe pump policy as it is now being used

Resolved: Ranitidine monograph acknowledged.

2018/138: NICE RECOMMENDATIONS (from July)

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer [TA528] is recommended as an option by NICE. Approved in line with NICE.

NHS England Cancer Drug Fund

Traffic Light: RED

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer [TA529] is recommended as an option by NICE. Approved in line with NICE.

NHS England Cancer Drug Fund

Traffic Light: RED

Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy [TA530] is not recommended as an option by NICE.

Traffic Light: BLACK

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [TA531] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Cenegermin for treating neurotrophic keratitissclerosis [TA532] is not recommended as an option by NICE.

NHS England Commissioned

Traffic Light: BLACK

Ocrelizumab for treating relapsing–remitting multiple sclerosis [TA533] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable [TA522 update] is recommended as an option by NICE. Approved in line with NICE.

NHS England Cancer Drug Fund

Traffic Light: RED

Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable [TA492 update] is recommended as an option by NICE. Approved in line with NICE.

NHS England Cancer Drug Fund

Traffic Light: RED

2018/139: NICE RECOMMENDATIONS (from August)

Dupilumab for treating moderate to severe atopic dermatitis (TA534) is recommended as an option by NICE. Approved in line with NICE. 30 day implementation
CCG Commissioned – Blueteq form required **Traffic Light: RED**

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535) are recommended as an option by NICE. Approved in line with NICE.
NHS England Commissioned **Traffic Light: RED**

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536) is recommended as an option by NICE. Approved in line with NICE.
NHS England Commissioned **Traffic Light: RED**

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537) is recommended as an option by NICE. Approved in line with NICE.
CCG Commissioned – Blueteq form required **Traffic Light: RED**

Dinutuximab beta for treating neuroblastoma (TA538) is recommended as an option by NICE. Approved in line with NICE.
NHS England Commissioned **Traffic Light: RED**

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539) is recommended as an option by NICE. Approved in line with NICE.
NHS England Commissioned **Traffic Light: RED**

2018/140: EAMS RECOMMENDATIONS

Patisiran-LNP is indicated for the treatment of adults with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). This is now closed

Closure of EAMS for - Nivolumab treatment as monotherapy for the treatment of adult patients with advanced or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma after two or more prior systemic therapies (Individual Patient Supply Request available)

STANDING ITEMS

2018/141: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – July 2018

Minutes acknowledged

2018/142: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – July 2018

Minutes acknowledged

DATE OF NEXT MEETING – Wednesday 17th October 2018 12.30pm, Seminar Room 2, Learning & Development Centre, RBH.

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 19TH SEPTEMBER 2018

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2018/052	LMMG Recommendations (from Feb LMMG) Melatonin guidelines – ELHT guideline – clarification on transitional information required.	VG	Oct 18
2018/073	Rifaxamin – Guidelines for Prescribing –Updated document sent to gastroenterology – awaiting comments	AG	Sept 18
2018/133	FORMULARY UPDATES Adrenaline autoinjectors - To produce & circulate HOT topic	LR	Oct 2018
2018/135	VITAMIN D SUPPLIES FOR PAEDIATRICS To produce & circulate HOT Topic	LR	Oct 2018